Elisha Hughes

1.9k total citations
38 papers, 1.1k citations indexed

About

Elisha Hughes is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, Elisha Hughes has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 12 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Elisha Hughes's work include BRCA gene mutations in cancer (24 papers), Cancer Genomics and Diagnostics (10 papers) and DNA Repair Mechanisms (8 papers). Elisha Hughes is often cited by papers focused on BRCA gene mutations in cancer (24 papers), Cancer Genomics and Diagnostics (10 papers) and DNA Repair Mechanisms (8 papers). Elisha Hughes collaborates with scholars based in United States, United Kingdom and Italy. Elisha Hughes's co-authors include Alexander Gutin, Allison W. Kurian, Jerry S. Lanchbury, Michael J. Hall, Zaina Sangale, Kirsten M. Timms, Brian Morris, Eric T. Rosenthal, M. D. Perry and Susanne Wagner and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Elisha Hughes

35 papers receiving 1.1k citations

Peers

Countries citing papers authored by Elisha Hughes

Since Specialization

Citations

This map shows the geographic impact of Elisha Hughes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisha Hughes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisha Hughes more than expected).

Fields of papers citing papers by Elisha Hughes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisha Hughes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisha Hughes. The network helps show where Elisha Hughes may publish in the future.

Co-authorship network of co-authors of Elisha Hughes

This figure shows the co-authorship network connecting the top 25 collaborators of Elisha Hughes. A scholar is included among the top collaborators of Elisha Hughes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisha Hughes. Elisha Hughes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1 , BRCA2 , ATM , CHEK2 , and PALB2 2025 ·Cancer Research Communications ·Allison W. Kurian, Elisha Hughes, Ryan Bernhisel, (unknown), Eric C. Polley, Siddhartha Yadav, Chunling Hu, Jennifer L. Caswell‐Jin, Esther M. John, Aladdin H. Shadyab, Rowan T. Chlebowski, Rami Nassir, Peter Kraft, Marcia L. Stefanick, Fergus J. Couch	0
2	The association between age at breast cancer diagnosis and prevalence of pathogenic variants 2023 ·Breast Cancer Research and Treatment ·Mary B. Daly, Eric T. Rosenthal, Shelly Cummings, Ryan Bernhisel, John Kidd, Elisha Hughes, Alexander Gutin, Stephanie Meek, Thomas P. Slavin, Allison W. Kurian	5
3	Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing 2023 ·JCO Precision Oncology ·Shelly Cummings, (unknown), Elisha Hughes, (unknown), (unknown), Nanda Singh, Charis Eng	11
4	Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated ( ATM ) Gene are Associated with High and Moderate Risks for Multiple Cancers 2021 ·Cancer Prevention Research ·Michael J. Hall, Ryan Bernhisel, Elisha Hughes, (unknown), Eric T. Rosenthal, Nanda A. Singh, Johnathan M. Lancaster, Allison W. Kurian	102
5	Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model 2021 ·JCO Precision Oncology ·Shannon Gallagher, Elisha Hughes, Allison W. Kurian, Susan M. Domchek, Judy E. Garber, (unknown), Brian Morris, (unknown), Stephanie Meek, Eric T. Rosenthal, Benjamin B. Roa, Thomas P. Slavin, Susanne Wagner, Jeffrey N. Weitzel, Alexander Gutin, Jerry S. Lanchbury, Mark E. Robson	14
6	Multigene assessment of genetic risk for women for two or more breast cancers 2021 ·Breast Cancer Research and Treatment ·Jeffrey N. Weitzel, John Kidd, Ryan Bernhisel, (unknown), Paul Frankel, Kathleen R. Blazer, (unknown), Bita Nehoray, (unknown), (unknown), Krystal Brown, (unknown), Mary B. Daly, Elisha Hughes, Shelly Cummings, Jennifer Saam, Thomas P. Slavin	5
7	Local injection of a hexametaphosphate formulation reduces heterotopic ossification in vivo 2020 ·Materials Today Bio ·Thomas E. Robinson, Neil Eisenstein, Sophie C. Cox, Richard J. A. Moakes, A.M. Thompson, Zubair Ahmed, Elisha Hughes, Lisa J. Hill, S Stapley, Liam M. Grover	11
8	Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy 2018 ·Molecular Cancer Research ·Euan A. Stronach, James Paul, Kirsten M. Timms, Elisha Hughes, Krystal Brown, Christopher Neff, M. D. Perry, Alexander Gutin, Mona El‐Bahrawy, Jennifer H. Steel, Xinxue Liu, Liz-Anne Lewsley, Nadeem Siddiqui, Hani Gabra, Jerry S. Lanchbury, Robert Brown	81
9	Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer 2017 ·Breast Cancer Research and Treatment ·Melinda L. Telli, Jessica A. Hellyer, William Audeh, Kristin C. Jensen, Shikha Bose, Kirsten M. Timms, Alexander Gutin, Victor Abkevich, (unknown), Chris Neff, Elisha Hughes, Zaina Sangale, Joshua T. Jones, Anne-Renee Hartman, Pei-Jen Chang, Shaveta Vinayak, Richard Wenstrup, James M. Ford	78
10	Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women 2017 ·JCO Precision Oncology ·Allison W. Kurian, Elisha Hughes, Elizabeth A. Handorf, Alexander Gutin, Brian Allen, Anne‐Renee Hartman, Michael J. Hall	131
11	Development and validation of a residual risk score to predict breast cancer risk in unaffected women negative for mutations on a multi-gene hereditary cancer panel. 2017 ·Journal of Clinical Oncology ·Elisha Hughes, Thaddeus Judkins, Susanne Wagner, Richard Wenstrup, Jerry S. Lanchbury, Alexander Gutin	7
12	3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC) 2016 ·Annals of Oncology ·Jerry S. Lanchbury, Kirsten M. Timms, (unknown), Euan A. Stronach, Alexander Gutin, Thomas C. Krivak, Bryan T. Hennessy, James Paul, Robert Brown, Rebecca N. Nix, Zaina Sangale, Elisha Hughes, Victor Abkevich, Gordon B. Mills	3
13	Prediction of distant recurrence in resected stage I and II lung adenocarcinoma 2016 ·Lung Cancer ·Beatrice Aramini, Christian Casali, Alessandro Stefani, Stefania Bettelli, Susanne Wagner, Zaina Sangale, Elisha Hughes, Jerry S. Lanchbury, Antonino Maiorana, Uliano Morandi	20
14	Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm 2016 ·BMC Genetics ·Brian Morris, Elisha Hughes, Eric T. Rosenthal, Alexander Gutin, Karla R. Bowles	12
15	Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women. 2016 ·Journal of Clinical Oncology ·Allison W. Kurian, Elisha Hughes, Elizabeth A. Handorf, Alexander Gutin, Brian Allen, Anne‐Renee Hartman, Michael J. Hall	2
16	Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators 2015 ·European Journal of Cancer ·Emad A. Rakha, María J. Pajares, Marius Ilié, Rubén Pı́o, José I. Echeveste, Elisha Hughes, Irshad Soomro, Élodie Long-Mira, Miguel Á. Idoate, Susanne Wagner, Jerry S. Lanchbury, David Baldwin, Paul Hofman, Luis M. Montuenga	5
17	Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes 2014 ·Breast Cancer Research and Treatment ·Dmitry Pruss, Brian Morris, Elisha Hughes, Julie M. Eggington, Lisa E. Esterling, (unknown), (unknown), (unknown), Benjamin B. Roa, Alexander Gutin, Richard Wenstrup, Karla R. Bowles	33
18	Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma 2014 ·Journal of Thoracic Oncology ·Raphael Bueno, Elisha Hughes, Susanne Wagner, Alexander Gutin, Jerry S. Lanchbury, Yifan Zheng, Michael A. Archer, Corinne E. Gustafson, Joshua T. Jones, Kristen Rushton, Jennifer Saam, Edward Kim, Massimo Barberis, Ignacio I. Wistuba, Richard Wenstrup, William Wallace, Anne-Renee Hartman, David J. Harrison	39
19	Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes 2014 ·Breast Cancer Research ·Kirsten M. Timms, Victor Abkevich, Elisha Hughes, Chris Neff, Julia Reid, Brian Morris, (unknown), Jennifer Potter, Thanh V. Tran, Jian Chen, Diana Iliev, Zaina Sangale, Eliso Tikishvili, M. D. Perry, Andrey Zharkikh, Alexander Gutin, Jerry S. Lanchbury	273
20	Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma 2013 ·Clinical Cancer Research ·Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Junya Fujimoto, Maria Gabriela Raso, Lorenzo Spaggiari, Domenico Galetta, Robyn Riley, Elisha Hughes, Julia Reid, Zaina Sangale, S.G. Swisher, Neda Kalhor, César A. Moran, Alexander Gutin, Jerry S. Lanchbury, Massimo Barberis, Edward S. Kim	84

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact